ClinicalTrials.Veeva

Menu

Diabetes Remission and Hypoabsorptive Bariatric Surgery (DIABAR-3)

C

Catalan Institute of Health

Status

Invitation-only

Conditions

Bariatric Surgery Candidate
Diabetes Mellitus, Type 2
Severe Obesity

Treatments

Procedure: Duodenal Switch
Procedure: Minigastric Bypass
Procedure: SADI-S

Study type

Interventional

Funder types

Other

Identifiers

NCT06043245
PR015/23

Details and patient eligibility

About

Bariatric surgery is the most effective treatment to achieve type 2 Diabetes Mellitus (DM) remission in patients with severe obesity. However, there is little evidence of the effectiveness and pathophysiological mechanisms involved in metabolic improvement after hypoabsortive tecniques such as duodenal switch (DS), single anastomosis duodenal switch (SADI-S) or minigastric bypass (MGB). We have designed a randomized study to compare type 2 diabetes remission after the 3 bariatric procedures in patients with severe obesity (BMI > 45kg/m2) and to study the implication of gastrointestinal hormones, bile acids and gut microbiota in metabolic improvement in each procedure.

Full description

Patients fulfilling inclusion criteria will be randomly assigned 1:1:1 to undergo DS, SADI-S or MGB. Allocation of patients will be assigned by simple randomization with stratification according to baseline levels of HbA1c (greater or lower/ equal to 7 %).

Protocol 0. Screening visit: All participants will be required to sign the informed consent, according to the regulations of the Committee of the center. Clinical, analytical, and general physical examination data will be collected and it will be checked the fulfillment of inclusion criteria.

  1. Visit 1 (1 week after screening visit): Anthropometrical data will be collected, and general biochemical analytics including HbA1c, lipid profile and nutritional parameters and vitamins will be performed. Also a standard meal test (SMT) will be done with determination of GLP-1, PYY, GIP , and ghrelin, insulin, glucose and succinate concentrations before and during the SMT. A complete body composition study including DEXA, BIA and cardiac resonance to determine epicardia fat will be performed. Feces samples will be collected to determine gut microbiota. Quality of live questionnaire will be provided.
  2. Visit2 (1 month after surgery): Glycaemia diaries will be checked. Anthropometrical, general biochemical analysis with determination of HbA1c, lipid profile and nutritional parameters and vitamins will be done. SMT will be performed with determination of GLP-1, PYY, GIP, ghrelin, insulin, glucose. A determination of bile acids will be done before starting the meal test. feces samples will be collected to determine gut microbiota.
  3. Visit 3 (3 months after surgery): Glycaemia diaries will be checked. Anthropometrical, general biochemical analysis with determination of HbA1c, lipid profile and nutritional parameters and vitamins will be done.
  4. Visit 4 (12 months after surgery): The same determinations of visit 1 will be performed 12 months after surgery.

Enrollment

66 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • BMI>45 kg/m2
  • T2D on treatment with hypoglycemic agents alone, insulin or both.

Exclusion criteria

  • Type 1 diabetes
  • Positivity for GAD auto-antibodies
  • Secondary forms of diabetes
  • Acute metabolic complications in the last 6 months
  • Severe liver disease
  • Renal dysfunction
  • Patients under anticoagulant treatment
  • Previous bariatric surgery
  • Congenital or acquired abnormalities of the digestive tract
  • Pregnancy
  • Nursing or desired pregnancy in the 12 months following inclusion
  • Corticoid use by oral or intravenous route for more than 14 consecutive days in the last three months.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

66 participants in 3 patient groups

Duodenal switch
Active Comparator group
Description:
The restrictive portion of the surgery involves removing approximately 70% of the stomach (along the greater curvature) and most of the duodenum. The malabsorptive portion of the surgery reroutes a lengthy portion of the small intestine, creating two separate pathways and one common channel.The common channel is 200 cm and 100m the alimentary limb.
Treatment:
Procedure: Duodenal Switch
SADI-S
Active Comparator group
Description:
Creation of a sleeve gastrectomy (SG) and a duodenal-ileal anastomosis with preservation of the pylorus, jejunal exclusion and a total common-alimentary limb, originally measuring 200 cm and later standardized to 300 cm to reduce the risk of nutritional deficiencies.
Treatment:
Procedure: SADI-S
Minigastric bypass
Active Comparator group
Description:
Creation of a gastric pouch similar to Sleeve gastrectomy and the small bowel is run to 200 cm distal to Treitz' ligament and then anastomosed antecolic end-to-side to the gastric pouch.
Treatment:
Procedure: Minigastric Bypass

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems